Friday, March 06, 2015 12:06:47 PM
Fraunhofer
http://www.fhcmb.org/
http://www.ntnv.org/sponsorship-opportunities/
NEWARK, Del.--(BUSINESS WIRE)--More than 100 scientists, business leaders and regulatory agency representatives from around the world will convene at the Hotel DuPont in Wilmington, DE from March 22–25, 2015 for the 10th anniversary of the New Technologies, New Vaccines conference, to share advancements in the fight against deadly diseases and prevention of potential epidemics including chikungunya, dengue, Ebola, influenza and HIV.
“With the growing global demand for vaccines and other biologics, the need for new high-performance technologies for vaccine identification, design, development and manufacturing is critical”
The 3-day conference brings together leaders from business and industry, academia and government to discuss latest developments in therapeutic treatments and life-saving vaccines. The event is organized by Fraunhofer USA Center for Molecular Biotechnology (CMB), located at the Delaware Technology Park in Newark, Delaware, in cooperation with the International Association for Biological Standardization (IABS), headquartered in Geneva, Switzerland.
Initiated in 2006, the conference explores how new technologies are enhancing our ability to identify and design new vaccine candidates, develop safe and effective vaccine formulations using improved drug-enhancing agents and delivery mechanisms, and providing innovative manufacturing platforms to produce vaccines more safely, quickly and economically than traditional approaches.
“With the growing global demand for vaccines and other biologics, the need for new high-performance technologies for vaccine identification, design, development and manufacturing is critical,” explained Fraunhofer USA CMB Executive Director Dr. Vidadi Yusibov.
One such bio-manufacturing platform is plants - highlighted in recent efforts by the Biomedical Advanced Research and Development Authority (BARDA) for manufacturing the Ebola monoclonal antibody-based therapeutic, ZMAPP.
“During the conference, we will share new knowledge and facilitate discussions and potential collaborations among representatives from academic research, government and industry fostering additional discoveries and development of new tools for effective prevention of global epidemic threats,” Yusibov added.
Featured keynote speaker Kathryn Zoon, Ph.D., Director of the Division of Intramural Research (DIR) at National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), will present on the stages of vaccine development and current challenges. Dr. Zoon provides overall executive direction and scientific leadership for the division’s basic and clinical research activities, which cover a wide range of biomedical disciplines related to infectious diseases, immunology and allergy.
Additional topics planned over the 3-day conference include next generation products for prevention and treatment of auto-immune diseases such as cancer, HSV and HIV, advancements in protein expression and production methods and regulatory considerations for new technologies.
Conference registration and additional information is available online at www.ntnv.org.
------------------
iBio Adds Anthrax Antibodies to Product Pipeline
http://globalbiodefense.com/2015/02/26/ibio-adds-anthrax-antibodies-to-product-pipeline/
The company’s technology has been successfully applied to the development of an anthrax vaccine candidate, and a Phase 1 clinical trial of the safety and immunogenicity of this experimental vaccine, produced at the Fraunhofer USA Center for Molecular Biotechnology under a research license from iBio, is being conducted at Walter Reed Army Institute of Research. - See more at: http://globalbiodefense.com/2015/02/26/ibio-adds-anthrax-antibodies-to-product-pipeline/#sthash.e4aHP2FD.dpuf
Recent IBIO News
- iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases • GlobeNewswire Inc. • 03/27/2024 11:00:00 AM
- iBio Announces $15.0 Million Private Placement • GlobeNewswire Inc. • 03/26/2024 11:35:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:59:30 PM
- iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka • GlobeNewswire Inc. • 02/26/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:55:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:36:09 PM
- iBio Announces Participation in 23rd Annual PepTalk Conference • GlobeNewswire Inc. • 01/16/2024 01:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/10/2024 06:24:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:30:59 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/04/2024 01:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 12:44:38 PM
- iBio Amends and Extends Maturity of Credit Agreement • GlobeNewswire Inc. • 12/26/2023 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 09:17:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 02:13:08 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/06/2023 01:59:51 PM
- iBio, Inc. Announces Pricing of $4.5 Million Public Offering • GlobeNewswire Inc. • 12/05/2023 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/05/2023 05:15:18 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/30/2023 01:55:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 01:36:43 PM
- iBio Announces Reverse Stock Split • GlobeNewswire Inc. • 11/27/2023 10:20:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:01:14 PM
- iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific • GlobeNewswire Inc. • 11/01/2023 12:24:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/27/2023 08:29:45 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/26/2023 12:20:58 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM